Anne Wojcicki, co-founder and former CEO of 23andMe, outbid Regeneron by securing the company's assets in a $305 million purchase through her nonprofit TTAM Research Institute. The deal ensures commitments to privacy and consumer control of genetic data, with protections against future data transfers without user consent. The acquisition aims to preserve 23andMe's founding mission amid financial distress and ongoing bankruptcy proceedings.